- Home
- TRVI vs TYRA Comparison
TRVI vs TYRA Comparison
Compare TRVI & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRVI
- TYRA
- Stock Information
- Founded
- TRVI 2011
- TYRA 2018
- Country
- TRVI United States
- TYRA United States
- Employees
- TRVI N/A
- TYRA 60
- Industry
- TRVI Biotechnology: Pharmaceutical Preparations
- TYRA Biotechnology: Pharmaceutical Preparations
- Sector
- TRVI Health Care
- TYRA Health Care
- Exchange
- TRVI Nasdaq
- TYRA Nasdaq
- Market Cap
- TRVI 725.7M
- TYRA 586.6M
- IPO Year
- TRVI 2019
- TYRA 2021
- Fundamental
- Price
- TRVI $7.42
- TYRA $10.45
- Analyst Decision
- TRVI Strong Buy
- TYRA Strong Buy
- Analyst Count
- TRVI 9
- TYRA 7
- Target Price
- TRVI $19.50
- TYRA $30.86
- AVG Volume (30 Days)
- TRVI 1.8M
- TYRA 215.6K
- Earning Date
- TRVI 08-07-2025
- TYRA 08-19-2025
- Dividend Yield
- TRVI N/A
- TYRA N/A
- EPS Growth
- TRVI N/A
- TYRA N/A
- EPS
- TRVI N/A
- TYRA N/A
- Revenue
- TRVI N/A
- TYRA N/A
- Revenue This Year
- TRVI N/A
- TYRA N/A
- Revenue Next Year
- TRVI N/A
- TYRA N/A
- P/E Ratio
- TRVI N/A
- TYRA N/A
- Revenue Growth
- TRVI N/A
- TYRA N/A
- 52 Week Low
- TRVI $2.36
- TYRA $6.42
- 52 Week High
- TRVI $8.11
- TYRA $29.60
- Technical
- Relative Strength Index (RSI)
- TRVI 59.47
- TYRA 48.16
- Support Level
- TRVI $7.08
- TYRA $10.00
- Resistance Level
- TRVI $7.74
- TYRA $11.72
- Average True Range (ATR)
- TRVI 0.42
- TYRA 0.67
- MACD
- TRVI -0.05
- TYRA -0.06
- Stochastic Oscillator
- TRVI 55.77
- TYRA 26.16
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.